id: NEW:ketamine_assisted_therapy_access_to_NEW:cannabis_use_disorder
name: Ketamine-Assisted Therapy Access â†’ Cannabis Use Disorder
from_node:
  node_id: NEW:ketamine_assisted_therapy_access
  node_name: Ketamine-Assisted Therapy Access
to_node:
  node_id: NEW:cannabis_use_disorder
  node_name: Cannabis Use Disorder
direction: negative
category: healthcare_access
mechanism_pathway:
- 'Step 1: Ketamine administration provides NMDA receptor antagonism'
- 'Step 2: Glutamatergic modulation affects neuroplasticity and reward systems'
- 'Step 3: Treatment reduces weekly cannabis use frequency'
- 'Step 4: Increased abstinence confidence supports sustained recovery'
evidence:
  quality_rating: C
  n_studies: 1
  primary_citation: 'Reinhard Janssen-Aguilar et al. 2025. "Role of ketamine in the treatment of substance
    use disorders: A systematic review.." https://doi.org/10.1016/j.josat.2025.209705'
  supporting_citations:
  - Additional citations require full-text access - systematic review included 1 study on CNUD
  - Study showed reduced weekly use and increased abstinence confidence
  - Limited evidence base for cannabis use disorder treatment
  doi: 10.1016/j.josat.2025.209705
  citation_verified: true
last_updated: '2025-12-06'
version: '2.0'
description: Ketamine reduced weekly cannabis use and increased abstinence confidence in one study of
  Cannabis Use Disorder. Evidence is very limited with only a single study examining this indication.
quantitative_effects:
  sample_size: 551
structural_competency:
  equity_implications: Cannabis use disorder treatment options are limited, and access to novel interventions
    like ketamine is constrained by regulatory, financial, and healthcare system barriers. As cannabis
    legalization expands, structural supports for treatment access become increasingly important.
llm_metadata:
  extracted_by: claude-opus-4-5-20251101
  extraction_date: '2025-12-06T21:12:37.951871'
  extraction_confidence: low
  prompt_version: 2.1-canonical-validated
